KR20110055715A - N-설폰아미도 폴리사이클릭 피라졸릴 화합물 - Google Patents
N-설폰아미도 폴리사이클릭 피라졸릴 화합물 Download PDFInfo
- Publication number
- KR20110055715A KR20110055715A KR1020117007863A KR20117007863A KR20110055715A KR 20110055715 A KR20110055715 A KR 20110055715A KR 1020117007863 A KR1020117007863 A KR 1020117007863A KR 20117007863 A KR20117007863 A KR 20117007863A KR 20110055715 A KR20110055715 A KR 20110055715A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- sulfonyl
- trifluoromethyl
- phenyl
- pyrazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 210
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims abstract description 150
- 238000000034 method Methods 0.000 claims abstract description 44
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 42
- SVSARCCKBMZNMR-UHFFFAOYSA-N [1-[2-[methyl-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethyl]amino]ethyl]pyridin-4-ylidene]methyl-oxoazanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1CCN(C)CCN1C=CC(=C[NH+]=O)C=C1 SVSARCCKBMZNMR-UHFFFAOYSA-N 0.000 claims abstract description 16
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 571
- 229910052736 halogen Inorganic materials 0.000 claims description 540
- 150000002367 halogens Chemical class 0.000 claims description 508
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 359
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 294
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 283
- -1 pyrazolidinonyl Chemical group 0.000 claims description 280
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 202
- 125000003118 aryl group Chemical group 0.000 claims description 155
- 125000005843 halogen group Chemical group 0.000 claims description 140
- 229910052739 hydrogen Inorganic materials 0.000 claims description 133
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 129
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 128
- 229910052799 carbon Inorganic materials 0.000 claims description 127
- 125000001072 heteroaryl group Chemical group 0.000 claims description 122
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 104
- 125000000335 thiazolyl group Chemical group 0.000 claims description 94
- 125000002883 imidazolyl group Chemical group 0.000 claims description 91
- 125000004076 pyridyl group Chemical group 0.000 claims description 91
- 229910052731 fluorine Inorganic materials 0.000 claims description 88
- 125000000217 alkyl group Chemical group 0.000 claims description 85
- 229910052801 chlorine Inorganic materials 0.000 claims description 81
- 125000003545 alkoxy group Chemical group 0.000 claims description 71
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 71
- 125000001188 haloalkyl group Chemical group 0.000 claims description 67
- 125000004043 oxo group Chemical group O=* 0.000 claims description 66
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 65
- 229910052794 bromium Inorganic materials 0.000 claims description 65
- 125000002971 oxazolyl group Chemical group 0.000 claims description 55
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 54
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 52
- 125000001624 naphthyl group Chemical group 0.000 claims description 51
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 50
- 239000001257 hydrogen Substances 0.000 claims description 50
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 48
- 125000001544 thienyl group Chemical group 0.000 claims description 48
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 47
- 125000002541 furyl group Chemical group 0.000 claims description 45
- 125000005605 benzo group Chemical group 0.000 claims description 44
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 44
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 41
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 41
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 41
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 38
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 38
- 125000003386 piperidinyl group Chemical group 0.000 claims description 37
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 37
- 125000001425 triazolyl group Chemical group 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- 125000001041 indolyl group Chemical group 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 125000002757 morpholinyl group Chemical group 0.000 claims description 34
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 33
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 27
- 150000001721 carbon Chemical group 0.000 claims description 25
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 25
- 125000002252 acyl group Chemical group 0.000 claims description 24
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 23
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 21
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 20
- 125000003282 alkyl amino group Chemical group 0.000 claims description 19
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 19
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 18
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 18
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 17
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 claims description 16
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 14
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 14
- 230000004770 neurodegeneration Effects 0.000 claims description 14
- 125000004104 aryloxy group Chemical group 0.000 claims description 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 11
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 11
- 125000006643 (C2-C6) haloalkenyl group Chemical group 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 9
- 206010012289 Dementia Diseases 0.000 claims description 9
- 125000004193 piperazinyl group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 6
- 201000010374 Down Syndrome Diseases 0.000 claims description 6
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 210000004558 lewy body Anatomy 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 73
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 73
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 44
- UREWVVFRSGFOEL-UHFFFAOYSA-N cyclohepta[c]pyrazole Chemical compound C1=CC=CC=C2C=NN=C21 UREWVVFRSGFOEL-UHFFFAOYSA-N 0.000 claims 33
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 13
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 12
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 8
- 230000000302 ischemic effect Effects 0.000 claims 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000014674 injury Diseases 0.000 claims 6
- 230000002207 retinal effect Effects 0.000 claims 6
- 230000008733 trauma Effects 0.000 claims 6
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 206010044688 Trisomy 21 Diseases 0.000 claims 4
- 208000029028 brain injury Diseases 0.000 claims 4
- 230000002490 cerebral effect Effects 0.000 claims 4
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- GPRLUZMQXAIJFJ-UHFFFAOYSA-N (4z,6z,8z)-1h-cycloocta[c]pyrazole Chemical compound C/1=C/C=C\C=C/C2=C\1NN=C2 GPRLUZMQXAIJFJ-UHFFFAOYSA-N 0.000 claims 3
- WUQDUTFTTFEVBT-UHFFFAOYSA-N 10-fluoro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound N1N=CC2=C1CC1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 WUQDUTFTTFEVBT-UHFFFAOYSA-N 0.000 claims 3
- AXRMLETUVFOEGG-UHFFFAOYSA-N 11-fluoro-13-methyl-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=2C(C)=CC(F)=CC=2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 AXRMLETUVFOEGG-UHFFFAOYSA-N 0.000 claims 3
- BHOIZHXQNAQNDM-UHFFFAOYSA-N 12-chloro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=C(Cl)C=C12 BHOIZHXQNAQNDM-UHFFFAOYSA-N 0.000 claims 3
- XAGIJOHXUNDGDQ-UHFFFAOYSA-N 13-fluoro-15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=2C(F)=CC=CC=2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 XAGIJOHXUNDGDQ-UHFFFAOYSA-N 0.000 claims 3
- LPGNFEMHCAETQT-UHFFFAOYSA-N 13-fluoro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=2C(F)=CC=CC=2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 LPGNFEMHCAETQT-UHFFFAOYSA-N 0.000 claims 3
- LAOYPXQZBFCCPD-UHFFFAOYSA-N 14-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-10-thia-4,5,12,14-tetrazatetracyclo[6.5.1.02,6.09,13]tetradeca-2(6),3,9(13),11-tetraene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=C2N=CS1 LAOYPXQZBFCCPD-UHFFFAOYSA-N 0.000 claims 3
- YTKPUCGEYIEMSQ-UHFFFAOYSA-N 15-(4-chlorophenyl)sulfonyl-13-fluoro-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaen-7-one Chemical compound C1=NNC(C2=O)=C1C1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(Cl)C=C1 YTKPUCGEYIEMSQ-UHFFFAOYSA-N 0.000 claims 3
- SONMNLUMLBERFJ-UHFFFAOYSA-N 15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=CC=C12 SONMNLUMLBERFJ-UHFFFAOYSA-N 0.000 claims 3
- XMZJFGJDGLSCRD-UHFFFAOYSA-N 19-[4-(trifluoromethyl)phenyl]sulfonyl-15,16,19-triazapentacyclo[10.6.1.02,11.03,8.013,17]nonadeca-2(11),3,5,7,9,13(17),14-heptaene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=C3C=CC=CC3=CC=C12 XMZJFGJDGLSCRD-UHFFFAOYSA-N 0.000 claims 3
- PZTOCUZOSPFKQZ-UHFFFAOYSA-N 7,7,13-trifluoro-15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=NNC(C2(F)F)=C1C1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 PZTOCUZOSPFKQZ-UHFFFAOYSA-N 0.000 claims 3
- ZVMAHZWUDYKAJT-UHFFFAOYSA-N 9-phenyl-12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C(C=1C=CC=CC=1)CC2 ZVMAHZWUDYKAJT-UHFFFAOYSA-N 0.000 claims 3
- VTVZNYAJEPPMGO-UHFFFAOYSA-N C12=CC(C(=O)OC)=CC=C2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 Chemical compound C12=CC(C(=O)OC)=CC=C2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 VTVZNYAJEPPMGO-UHFFFAOYSA-N 0.000 claims 3
- BGXCRHVOAPQTIS-UHFFFAOYSA-N C1=2C(F)=CC=CC=2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(Cl)C=C1 Chemical compound C1=2C(F)=CC=CC=2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(Cl)C=C1 BGXCRHVOAPQTIS-UHFFFAOYSA-N 0.000 claims 3
- WVHPESSRIMHJJY-UHFFFAOYSA-N N1N=CC2=C1CC1C=3C(F)=CC=CC=3CC2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 Chemical compound N1N=CC2=C1CC1C=3C(F)=CC=CC=3CC2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 WVHPESSRIMHJJY-UHFFFAOYSA-N 0.000 claims 3
- HWZSDECUKARGIQ-UHFFFAOYSA-N chembl1837048 Chemical compound FC1=CC=CC(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=NC(=CC=3)C(F)(F)F)C2)=C1 HWZSDECUKARGIQ-UHFFFAOYSA-N 0.000 claims 3
- SKKNGTJHVDVDQB-UHFFFAOYSA-N chembl571186 Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1C2CC(C#N)CC1CC1=C2C=NN1 SKKNGTJHVDVDQB-UHFFFAOYSA-N 0.000 claims 3
- OMBNWRCJUMAOGY-UHFFFAOYSA-N methyl 15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene-10-carboxylate Chemical compound N1N=CC2=C1CC1C=3C(C(=O)OC)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 OMBNWRCJUMAOGY-UHFFFAOYSA-N 0.000 claims 3
- MYQQZBPXYQRKIU-UHFFFAOYSA-N 10-chloro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=C(Cl)C=CC=C12 MYQQZBPXYQRKIU-UHFFFAOYSA-N 0.000 claims 2
- SHQVIXPYJLOUIP-UHFFFAOYSA-N 12-bromo-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,13,15-tetrazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=C(Br)N=C12 SHQVIXPYJLOUIP-UHFFFAOYSA-N 0.000 claims 2
- SFXDZFWHZSQBJK-UHFFFAOYSA-N 12-fluoro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C12=CC(F)=CC=C2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 SFXDZFWHZSQBJK-UHFFFAOYSA-N 0.000 claims 2
- DFOQDRDKMQKNQI-UHFFFAOYSA-N 15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,10,15-tetrazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=NC=CC=C12 DFOQDRDKMQKNQI-UHFFFAOYSA-N 0.000 claims 2
- DJPISMZFHGHKBX-UHFFFAOYSA-N 15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,13,15-tetrazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=CN=C12 DJPISMZFHGHKBX-UHFFFAOYSA-N 0.000 claims 2
- AYFGISGEVPLQGS-UHFFFAOYSA-N 15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=CC=C12 AYFGISGEVPLQGS-UHFFFAOYSA-N 0.000 claims 2
- IOGYGVYXDUMWGA-UHFFFAOYSA-N 15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene-11-carbonitrile Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC(C#N)=CC=C12 IOGYGVYXDUMWGA-UHFFFAOYSA-N 0.000 claims 2
- HCLXLZGAYCTHQJ-UHFFFAOYSA-N 1h-cyclohepta[b]pyridine Chemical compound C1=CC=CC=C2NC=CC=C21 HCLXLZGAYCTHQJ-UHFFFAOYSA-N 0.000 claims 2
- GYFGMJUPZUUYKY-UHFFFAOYSA-N 3-bromo-16-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-12,13,16-triazatetracyclo[7.6.1.02,7.010,14]hexadeca-2(7),3,5,10(14),11-pentaene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C3=C(Br)C=CC=C3CC1C(C=NN1)=C1C2 GYFGMJUPZUUYKY-UHFFFAOYSA-N 0.000 claims 2
- LOMAEMKJOHISQZ-UHFFFAOYSA-N 3-bromo-16-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-12,13,16-triazatetracyclo[7.6.1.02,7.011,15]hexadeca-2(7),3,5,11(15),13-pentaene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1CC1=CC=CC(Br)=C12 LOMAEMKJOHISQZ-UHFFFAOYSA-N 0.000 claims 2
- CJHWBGRYNSGINR-UHFFFAOYSA-N 3-methyl-5-[15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaen-12-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2C=C3C4C=5C=NNC=5CC(N4S(=O)(=O)C=4C=NC(=CC=4)C(F)(F)F)C3=CC=2)=N1 CJHWBGRYNSGINR-UHFFFAOYSA-N 0.000 claims 2
- RXLJWRLNHRWBCH-UHFFFAOYSA-N 3-methyl-5-[15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaen-10-yl]-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2C=3C4N(C(C=5C=NNC=5C4)C=3C=CC=2)S(=O)(=O)C=2C=NC(=CC=2)C(F)(F)F)=N1 RXLJWRLNHRWBCH-UHFFFAOYSA-N 0.000 claims 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 2
- SJBBSCRLCUDUBL-UHFFFAOYSA-N C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=C2C2=CC=CC=C2C=C1 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=C2C2=CC=CC=C2C=C1 SJBBSCRLCUDUBL-UHFFFAOYSA-N 0.000 claims 2
- RJNYDZQFLJAULE-UHFFFAOYSA-N C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC(Cl)=CC=C12 Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC(Cl)=CC=C12 RJNYDZQFLJAULE-UHFFFAOYSA-N 0.000 claims 2
- HAZZTMGXPIMONG-UHFFFAOYSA-N C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=C(C3CC3)N=C12 Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=C(C3CC3)N=C12 HAZZTMGXPIMONG-UHFFFAOYSA-N 0.000 claims 2
- CWCIPSOPTBXNIK-UHFFFAOYSA-N C=1C=CC=C2C=1C1C=3C=NNC=3C(=O)C2(C)N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 Chemical compound C=1C=CC=C2C=1C1C=3C=NNC=3C(=O)C2(C)N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 CWCIPSOPTBXNIK-UHFFFAOYSA-N 0.000 claims 2
- SJMWMJWPMICQDP-UHFFFAOYSA-N CN1N=CC(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=CC(Cl)=CC=3)C2)=N1 Chemical compound CN1N=CC(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=CC(Cl)=CC=3)C2)=N1 SJMWMJWPMICQDP-UHFFFAOYSA-N 0.000 claims 2
- 206010012667 Diabetic glaucoma Diseases 0.000 claims 2
- MMKFJQJMWSBFPD-UHFFFAOYSA-N N1=NN(C)C=C1C1CC(N2S(=O)(=O)C=3C=CC(Cl)=CC=3)C(C=NN3)=C3CC2C1 Chemical compound N1=NN(C)C=C1C1CC(N2S(=O)(=O)C=3C=CC(Cl)=CC=3)C(C=NN3)=C3CC2C1 MMKFJQJMWSBFPD-UHFFFAOYSA-N 0.000 claims 2
- DBBDPKUPNWYZPS-UHFFFAOYSA-N N1N=CC2=C1CC1C3=CC(F)=CN=C3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 Chemical compound N1N=CC2=C1CC1C3=CC(F)=CN=C3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 DBBDPKUPNWYZPS-UHFFFAOYSA-N 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 230000003942 amyloidogenic effect Effects 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- GKBCARCQHHRETI-USXIJHARSA-N (1R,7R,8R)-7,13-difluoro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound N1([C@H]2[C@H](C=3NN=CC=3[C@@H]1C=1C(=CC=CC2=1)F)F)S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 GKBCARCQHHRETI-USXIJHARSA-N 0.000 claims 1
- GKBCARCQHHRETI-XIRDDKMYSA-N (1S,7R,8S)-7,13-difluoro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound N1([C@@H]2[C@H](C=3NN=CC=3[C@H]1C=1C(=CC=CC2=1)F)F)S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 GKBCARCQHHRETI-XIRDDKMYSA-N 0.000 claims 1
- CICHLBYBQZIZAR-OFLPRAFFSA-N (7S)-10-fluoro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaen-7-ol Chemical compound C1([C@@H](C=2NN=CC=2C2C=3C1=C(F)C=CC=3)O)N2S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 CICHLBYBQZIZAR-OFLPRAFFSA-N 0.000 claims 1
- MIGHYBXBFPKGML-UHFFFAOYSA-N 1-[4-[12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-dien-10-yl]phenyl]pyrrolidin-2-one Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3C(CCC3)=O)CC1CC1=C2C=NN1 MIGHYBXBFPKGML-UHFFFAOYSA-N 0.000 claims 1
- GPYVSQOCAZCYSL-UHFFFAOYSA-N 10-(1,3-benzodioxol-5-yl)-12-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=C4OCOC4=CC=3)CC1CC1=C2C=NN1 GPYVSQOCAZCYSL-UHFFFAOYSA-N 0.000 claims 1
- FKBKAYPHYYLBKX-UHFFFAOYSA-N 10-(2,5-dimethyl-1,2,4-triazol-3-yl)-12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound CN1N=C(C)N=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 FKBKAYPHYYLBKX-UHFFFAOYSA-N 0.000 claims 1
- CHYDKRQATUMQTP-UHFFFAOYSA-N 10-(3-bromophenyl)-12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=C(Br)C=CC=3)CC1CC1=C2C=NN1 CHYDKRQATUMQTP-UHFFFAOYSA-N 0.000 claims 1
- IIECBPYKHRNKON-UHFFFAOYSA-N 10-(3-imidazol-1-ylphenyl)-12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=C(C=CC=3)N3C=NC=C3)CC1CC1=C2C=NN1 IIECBPYKHRNKON-UHFFFAOYSA-N 0.000 claims 1
- VJBBVEGSZUEWTQ-UHFFFAOYSA-N 10-(3-pyrazol-1-ylphenyl)-12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=C(C=CC=3)N3N=CC=C3)CC1CC1=C2C=NN1 VJBBVEGSZUEWTQ-UHFFFAOYSA-N 0.000 claims 1
- KHRLSWLOHUGIMN-UHFFFAOYSA-N 10-(4-bromophenyl)-12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(Br)=CC=3)CC1CC1=C2C=NN1 KHRLSWLOHUGIMN-UHFFFAOYSA-N 0.000 claims 1
- JWGPBXFDPYYAGP-UHFFFAOYSA-N 10-(4-methoxyphenyl)-12-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1=CC(OC)=CC=C1C1CC(N2S(=O)(=O)C=3C=NC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 JWGPBXFDPYYAGP-UHFFFAOYSA-N 0.000 claims 1
- UVGIVEQBHQKKKR-UHFFFAOYSA-N 10-(4-pyrazol-1-ylphenyl)-12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3N=CC=C3)CC1CC1=C2C=NN1 UVGIVEQBHQKKKR-UHFFFAOYSA-N 0.000 claims 1
- LGZYIAUXBNPCCU-UHFFFAOYSA-N 10-[4-(1,2,4-triazol-1-yl)phenyl]-12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3N=CN=C3)CC1CC1=C2C=NN1 LGZYIAUXBNPCCU-UHFFFAOYSA-N 0.000 claims 1
- FLJYQRYVAFAIIW-UHFFFAOYSA-N 10-chloro-7-methylidene-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(=C)C(NN=C3)=C3C1C1=C2C(Cl)=CC=C1 FLJYQRYVAFAIIW-UHFFFAOYSA-N 0.000 claims 1
- UKVHTRHEAPQBHW-UHFFFAOYSA-N 11,12-difluoro-15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaen-7-one Chemical compound N1N=CC2=C1C(=O)C1C=3C=C(F)C(F)=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 UKVHTRHEAPQBHW-UHFFFAOYSA-N 0.000 claims 1
- SYNQSTLMIXGNQH-UHFFFAOYSA-N 11,12-difluoro-15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaene Chemical compound C1=2C=C(F)C(F)=CC=2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 SYNQSTLMIXGNQH-UHFFFAOYSA-N 0.000 claims 1
- YCLTZMRZEZEAOV-UHFFFAOYSA-N 11,12-difluoro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaen-7-one Chemical compound N1N=CC2=C1C(=O)C1C=3C=C(F)C(F)=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 YCLTZMRZEZEAOV-UHFFFAOYSA-N 0.000 claims 1
- COGPSDSDJBWMRQ-UHFFFAOYSA-N 11-phenyl-12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical class C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=3C=CC=CC=3)CCC1CC1=C2C=NN1 COGPSDSDJBWMRQ-UHFFFAOYSA-N 0.000 claims 1
- PLCGDCIKHKGJJI-UHFFFAOYSA-N 12-(4-chlorophenyl)sulfonyl-10-pyridin-4-yl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1C2CC(C=3C=CN=CC=3)CC1CC1=C2C=NN1 PLCGDCIKHKGJJI-UHFFFAOYSA-N 0.000 claims 1
- YQLKBYRERWEPIS-UHFFFAOYSA-N 12-cyclopropyl-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=C(C3CC3)C=C12 YQLKBYRERWEPIS-UHFFFAOYSA-N 0.000 claims 1
- PVXSHEWMWTYCAP-UHFFFAOYSA-N 13-chloro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=C2C(Cl)=CC=C1 PVXSHEWMWTYCAP-UHFFFAOYSA-N 0.000 claims 1
- FHTDRRPPSIIVKT-UHFFFAOYSA-N 13-fluoro-15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaen-7-one Chemical compound C1=NNC(C2=O)=C1C1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 FHTDRRPPSIIVKT-UHFFFAOYSA-N 0.000 claims 1
- NSXTXFTZKVIORX-UHFFFAOYSA-N 13-fluoro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaen-7-one Chemical compound C1=NNC(C2=O)=C1C1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 NSXTXFTZKVIORX-UHFFFAOYSA-N 0.000 claims 1
- APNOWSZCEWCWBX-UHFFFAOYSA-N 15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,11,15-tetrazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CN=CC=C12 APNOWSZCEWCWBX-UHFFFAOYSA-N 0.000 claims 1
- BCDXATZVEVRGMG-UHFFFAOYSA-N 15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaen-7-one Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(=O)C(NN=C3)=C3C1C1=CC=CC=C12 BCDXATZVEVRGMG-UHFFFAOYSA-N 0.000 claims 1
- LNNBVNKEPCPJFS-UHFFFAOYSA-N 2-N-[4-[12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-dien-10-yl]phenyl]cyclohexane-1,2-diamine Chemical compound NC1CCCCC1NC1=CC=C(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C2)C=C1 LNNBVNKEPCPJFS-UHFFFAOYSA-N 0.000 claims 1
- CDZCREIHDRCTHZ-UHFFFAOYSA-N 2h-cyclohepta[c]pyridine Chemical compound C1=CC=CC2=CNC=CC2=C1 CDZCREIHDRCTHZ-UHFFFAOYSA-N 0.000 claims 1
- RYIWNFGDJVFMGD-UHFFFAOYSA-N 4-[4-[12-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-dien-10-yl]phenyl]-1,3-thiazole Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)C=3N=CSC=3)CC1CC1=C2C=NN1 RYIWNFGDJVFMGD-UHFFFAOYSA-N 0.000 claims 1
- FRCKYHZZVAZMBD-UHFFFAOYSA-N 5-[12-(4-chlorophenyl)sulfonyl-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-dien-10-yl]-3-methyl-1,2-oxazole Chemical compound O1N=C(C)C=C1C1CC(N2S(=O)(=O)C=3C=CC(Cl)=CC=3)C(C=NN3)=C3CC2C1 FRCKYHZZVAZMBD-UHFFFAOYSA-N 0.000 claims 1
- YKAHJBZWTLSLDX-UHFFFAOYSA-N 6-[3-(trifluoromethyl)phenyl]-16-[4-(trifluoromethyl)phenyl]sulfonyl-12,13,16-triazatetracyclo[7.6.1.02,7.010,14]hexadeca-2,4,6,10(14),11-pentaene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=CC=C3C=4C=C(C=CC=4)C(F)(F)F)=C3CC1C(C=NN1)=C1C2 YKAHJBZWTLSLDX-UHFFFAOYSA-N 0.000 claims 1
- XXWFKZUTBAKMQQ-UHFFFAOYSA-N 6-[3-(trifluoromethyl)phenyl]-16-[4-(trifluoromethyl)phenyl]sulfonyl-12,13,16-triazatetracyclo[7.6.1.02,7.011,15]hexadeca-2,4,6,11(15),13-pentaene Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1CC1=C(C=3C=C(C=CC=3)C(F)(F)F)C=CC=C12 XXWFKZUTBAKMQQ-UHFFFAOYSA-N 0.000 claims 1
- IQWCJKNANUABPL-UHFFFAOYSA-N 6-cyclopropyl-16-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-12,13,16-triazatetracyclo[7.6.1.02,7.011,15]hexadeca-2,4,6,11(15),13-pentaene Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1CC1=C(C3CC3)C=CC=C12 IQWCJKNANUABPL-UHFFFAOYSA-N 0.000 claims 1
- APOOAIAIGJFPGE-UHFFFAOYSA-N 7,7,10-trifluoro-15-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound N1N=CC2=C1C(F)(F)C1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 APOOAIAIGJFPGE-UHFFFAOYSA-N 0.000 claims 1
- XVNAQZWJSJINLR-UHFFFAOYSA-N 7,7,11,12-tetrafluoro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaene Chemical compound N1N=CC2=C1C(F)(F)C1C=3C=C(F)C(F)=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 XVNAQZWJSJINLR-UHFFFAOYSA-N 0.000 claims 1
- WAFIKIXEWYWANV-UHFFFAOYSA-N 7,7,13-trifluoro-15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9(14),10,12-pentaene Chemical compound C1=NNC(C2(F)F)=C1C1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 WAFIKIXEWYWANV-UHFFFAOYSA-N 0.000 claims 1
- 241000125205 Anethum Species 0.000 claims 1
- CAGXPYAJPFEKDF-UHFFFAOYSA-N C12=CC(O)=CC=C2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 Chemical compound C12=CC(O)=CC=C2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 CAGXPYAJPFEKDF-UHFFFAOYSA-N 0.000 claims 1
- LHXPNPPXTYGLFO-UHFFFAOYSA-N C1=2C(F)=CC=CC=2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)C=N1 Chemical compound C1=2C(F)=CC=CC=2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)C=N1 LHXPNPPXTYGLFO-UHFFFAOYSA-N 0.000 claims 1
- GIKARRRTTYAGEA-UHFFFAOYSA-N C1=2C(F)=CC=CC=2CC2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 Chemical compound C1=2C(F)=CC=CC=2CC2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 GIKARRRTTYAGEA-UHFFFAOYSA-N 0.000 claims 1
- PPHWWWXAWQOTKJ-UHFFFAOYSA-N C1=CC(C(=O)C)=CC=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 Chemical compound C1=CC(C(=O)C)=CC=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 PPHWWWXAWQOTKJ-UHFFFAOYSA-N 0.000 claims 1
- QIZOOHRRVHPDAD-UHFFFAOYSA-N C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC(OC(=O)O3)=C3C=C12 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC(OC(=O)O3)=C3C=C12 QIZOOHRRVHPDAD-UHFFFAOYSA-N 0.000 claims 1
- GHESRBOHVXWZCE-UHFFFAOYSA-N C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC(OCO3)=C3C=C12 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC(OCO3)=C3C=C12 GHESRBOHVXWZCE-UHFFFAOYSA-N 0.000 claims 1
- GZHGNEVVXDOMHY-UHFFFAOYSA-N C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=NC=C12 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=NC=C12 GZHGNEVVXDOMHY-UHFFFAOYSA-N 0.000 claims 1
- VGZDBKSHIGNGSR-UHFFFAOYSA-N C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(F)(F)C(NN=C3)=C3C1C1=CC=CC=C12 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(F)(F)C(NN=C3)=C3C1C1=CC=CC=C12 VGZDBKSHIGNGSR-UHFFFAOYSA-N 0.000 claims 1
- MXTAXDQUAASAIJ-UHFFFAOYSA-N C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C3=CC=CC=C3CC1C(C=NN1)=C1C2 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C3=CC=CC=C3CC1C(C=NN1)=C1C2 MXTAXDQUAASAIJ-UHFFFAOYSA-N 0.000 claims 1
- FTWFXCFPSLTKBO-UHFFFAOYSA-N C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3C(CC3)=O)CC1CC1=C2C=NN1 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3C(CC3)=O)CC1CC1=C2C=NN1 FTWFXCFPSLTKBO-UHFFFAOYSA-N 0.000 claims 1
- ZPRUQFHRRGJCEQ-UHFFFAOYSA-N C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3C(COCC3)=O)CC1CC1=C2C=NN1 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3C(COCC3)=O)CC1CC1=C2C=NN1 ZPRUQFHRRGJCEQ-UHFFFAOYSA-N 0.000 claims 1
- KSFWXCFAHNLMHZ-UHFFFAOYSA-N C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3N=NSC=3)CC1CC1=C2C=NN1 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3N=NSC=3)CC1CC1=C2C=NN1 KSFWXCFAHNLMHZ-UHFFFAOYSA-N 0.000 claims 1
- VYLWGYPNPLKKRZ-UHFFFAOYSA-N C1=CC(Cl)=CC=C1S(=O)(=O)N1C2CC(C3=NNN=C3)CC1CC1=C2C=NN1 Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1C2CC(C3=NNN=C3)CC1CC1=C2C=NN1 VYLWGYPNPLKKRZ-UHFFFAOYSA-N 0.000 claims 1
- JSPOUIMZVUHFRV-UHFFFAOYSA-N C1=CC(F)=CC=C1C1=CC2C(C=NN3)=C3CC1N2S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 Chemical class C1=CC(F)=CC=C1C1=CC2C(C=NN3)=C3CC1N2S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 JSPOUIMZVUHFRV-UHFFFAOYSA-N 0.000 claims 1
- LSUKVCFBORQHPR-UHFFFAOYSA-N C1=CC(NC(=O)C)=CC=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 Chemical compound C1=CC(NC(=O)C)=CC=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 LSUKVCFBORQHPR-UHFFFAOYSA-N 0.000 claims 1
- LDVRGNRPBRDGFK-UHFFFAOYSA-N C1=CC(NCCOCC(=O)O)=CC=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 Chemical compound C1=CC(NCCOCC(=O)O)=CC=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 LDVRGNRPBRDGFK-UHFFFAOYSA-N 0.000 claims 1
- TZPGQZDUQXIBDJ-UHFFFAOYSA-N C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(=O)C(NN=C3)=C3C1C1=C2C(Cl)=CC=C1 Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(=O)C(NN=C3)=C3C1C1=C2C(Cl)=CC=C1 TZPGQZDUQXIBDJ-UHFFFAOYSA-N 0.000 claims 1
- XIQFPYYLCMDWKS-UHFFFAOYSA-N C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=C(Br)C=C12 Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C(C=NN3)=C3CC1C1=CC=C(Br)C=C12 XIQFPYYLCMDWKS-UHFFFAOYSA-N 0.000 claims 1
- MWABIHDBHOSMTC-UHFFFAOYSA-N C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C3=CC=CC(C4CC4)=C3CC1C(C=NN1)=C1C2 Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C3=CC=CC(C4CC4)=C3CC1C(C=NN1)=C1C2 MWABIHDBHOSMTC-UHFFFAOYSA-N 0.000 claims 1
- VNQODWBHNAITRN-UHFFFAOYSA-N C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C3=CC=CC=C3CC1C(C=NN1)=C1C2 Chemical compound C1=NC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2C3=CC=CC=C3CC1C(C=NN1)=C1C2 VNQODWBHNAITRN-UHFFFAOYSA-N 0.000 claims 1
- IQTUWCVLGOJOGD-UHFFFAOYSA-N C=12C=CC=C(F)C=1C1C=3C=NNC=3C(F)C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 Chemical compound C=12C=CC=C(F)C=1C1C=3C=NNC=3C(F)C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 IQTUWCVLGOJOGD-UHFFFAOYSA-N 0.000 claims 1
- PSWJAPFUIAEDNM-UHFFFAOYSA-N CC1(C)CC2CC=3NN=CC=3N1N2S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 Chemical compound CC1(C)CC2CC=3NN=CC=3N1N2S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 PSWJAPFUIAEDNM-UHFFFAOYSA-N 0.000 claims 1
- RAEZQPOUPDJJRK-UHFFFAOYSA-N CN1C=CC(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C2)=N1 Chemical compound CN1C=CC(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C2)=N1 RAEZQPOUPDJJRK-UHFFFAOYSA-N 0.000 claims 1
- VUSFHANERADPLI-UHFFFAOYSA-N CN1N=CC=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 Chemical compound CN1N=CC=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 VUSFHANERADPLI-UHFFFAOYSA-N 0.000 claims 1
- POMIBIVUEIDWTM-UHFFFAOYSA-N CN1N=NC=C1C1CC(N2S(=O)(=O)C=3C=CC(Cl)=CC=3)C(C=NN3)=C3CC2C1 Chemical compound CN1N=NC=C1C1CC(N2S(=O)(=O)C=3C=CC(Cl)=CC=3)C(C=NN3)=C3CC2C1 POMIBIVUEIDWTM-UHFFFAOYSA-N 0.000 claims 1
- WKVNKWUBYBWWPP-UHFFFAOYSA-N N1N=CC2=C1C(=O)C1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 Chemical compound N1N=CC2=C1C(=O)C1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 WKVNKWUBYBWWPP-UHFFFAOYSA-N 0.000 claims 1
- OUPPTQCQSOCETC-UHFFFAOYSA-N N1N=CC2=C1CC1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 Chemical compound N1N=CC2=C1CC1C=3C(F)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 OUPPTQCQSOCETC-UHFFFAOYSA-N 0.000 claims 1
- YOMTWQXKTDBHKD-UHFFFAOYSA-N N1N=CC2=C1CN1C(C)(C)CC2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 Chemical compound N1N=CC2=C1CN1C(C)(C)CC2N1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 YOMTWQXKTDBHKD-UHFFFAOYSA-N 0.000 claims 1
- VAODCQDBZRVRAE-UHFFFAOYSA-N [15-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaen-10-yl]methanol Chemical compound N1N=CC2=C1CC1C=3C(CO)=CC=CC=3C2N1S(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 VAODCQDBZRVRAE-UHFFFAOYSA-N 0.000 claims 1
- HOWZRGMUXMOUAI-UHFFFAOYSA-N chembl1837042 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC=CC=3)CC1CC1=C2C=NN1 HOWZRGMUXMOUAI-UHFFFAOYSA-N 0.000 claims 1
- WWBXWWWAZYGPBG-UHFFFAOYSA-N chembl1837044 Chemical compound S1C(Cl)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC=CC=3)CC1CC1=C2C=NN1 WWBXWWWAZYGPBG-UHFFFAOYSA-N 0.000 claims 1
- HIRONKBRYBENQL-UHFFFAOYSA-N chembl1837050 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3C(OCC3)=O)CC1CC1=C2C=NN1 HIRONKBRYBENQL-UHFFFAOYSA-N 0.000 claims 1
- RDNMKSJCMCSZGD-UHFFFAOYSA-N chembl1837051 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3C=NC=C3)CC1CC1=C2C=NN1 RDNMKSJCMCSZGD-UHFFFAOYSA-N 0.000 claims 1
- CUGHGQZFDYOJGX-UHFFFAOYSA-N chembl1837058 Chemical compound S1C(C)=NN=C1C1CC(N2S(=O)(=O)C=3C=CC(Cl)=CC=3)C(C=NN3)=C3CC2C1 CUGHGQZFDYOJGX-UHFFFAOYSA-N 0.000 claims 1
- ROCXIAVBNAMBLQ-UHFFFAOYSA-N chembl1837059 Chemical compound CC1=NOC(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=CC(Cl)=CC=3)C2)=N1 ROCXIAVBNAMBLQ-UHFFFAOYSA-N 0.000 claims 1
- SZVWQZIZRCBQFN-UHFFFAOYSA-N chembl1837060 Chemical compound FC(F)(F)C1=CSC(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=NC(=CC=3)C(F)(F)F)C2)=N1 SZVWQZIZRCBQFN-UHFFFAOYSA-N 0.000 claims 1
- GFLCDRXRUKOTNK-UHFFFAOYSA-N chembl1837062 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C3=NNC=N3)CC1CC1=C2C=NN1 GFLCDRXRUKOTNK-UHFFFAOYSA-N 0.000 claims 1
- NLWOLFNMAZDVBE-UHFFFAOYSA-N cyclohepta[c]pyrazole-8-carboxylic acid Chemical compound OC(=O)C1=CC=CC=C2C=NN=C12 NLWOLFNMAZDVBE-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 2
- 150000002923 oximes Chemical class 0.000 description 84
- 229920000728 polyester Polymers 0.000 description 72
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 23
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 23
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 20
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 18
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 15
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 15
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 15
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 14
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 14
- 102000005650 Notch Receptors Human genes 0.000 description 12
- 108010070047 Notch Receptors Proteins 0.000 description 12
- 102100022033 Presenilin-1 Human genes 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 102000015499 Presenilins Human genes 0.000 description 8
- 108010050254 Presenilins Proteins 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 108010036933 Presenilin-1 Proteins 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 125000002009 alkene group Chemical group 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000003540 gamma secretase inhibitor Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 4
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000579647 Penaeus vannamei Penaeidin-2a Proteins 0.000 description 4
- 102100022036 Presenilin-2 Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 3
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 3
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 3
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 3
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 description 3
- 206010059245 Angiopathy Diseases 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 3
- 102000001759 Notch1 Receptor Human genes 0.000 description 3
- 108010029755 Notch1 Receptor Proteins 0.000 description 3
- 101150089041 aph-1 gene Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108700022821 nicastrin Proteins 0.000 description 3
- 102000046701 nicastrin Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 2
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108010036908 Presenilin-2 Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102400000577 C83 Human genes 0.000 description 1
- 101800001508 C83 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 1
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000033026 cell fate determination Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- YPFLZILYILGHIK-UHFFFAOYSA-N ethyl 3-oxo-9-azabicyclo[3.3.1]nonane-7-carboxylate Chemical compound C1C(=O)CC2CC(C(=O)OCC)CC1N2 YPFLZILYILGHIK-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 150000004678 hydrides Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9479908P | 2008-09-05 | 2008-09-05 | |
| US61/094,799 | 2008-09-05 | ||
| US9924108P | 2008-09-23 | 2008-09-23 | |
| US61/099,241 | 2008-09-23 | ||
| US17327809P | 2009-04-28 | 2009-04-28 | |
| US61/173,278 | 2009-04-28 | ||
| US22653209P | 2009-07-17 | 2009-07-17 | |
| US61/226,532 | 2009-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110055715A true KR20110055715A (ko) | 2011-05-25 |
Family
ID=41258775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117007863A Withdrawn KR20110055715A (ko) | 2008-09-05 | 2009-09-04 | N-설폰아미도 폴리사이클릭 피라졸릴 화합물 |
Country Status (20)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009289649B2 (en) | 2008-09-03 | 2016-05-05 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
| US8283358B2 (en) | 2008-09-05 | 2012-10-09 | Elan Pharmaceuticals, Inc. | N-sulfonamido polycyclic pyrazolyl compounds |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| WO2012118782A1 (en) | 2011-02-28 | 2012-09-07 | Repligen Corporation | Histone deacetylase inhibitors |
| RU2665554C2 (ru) | 2013-03-15 | 2018-08-31 | Байомарин Фармасьютикал Инк. | Ингибиторы hdac |
| EP4084797A4 (en) * | 2020-01-03 | 2024-02-21 | Blue Oak Pharmaceuticals, Inc. | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISEASES |
| CN111909217B (zh) * | 2020-08-20 | 2023-05-02 | 昆明贵金属研究所 | 一种双(二叔丁基-4-二甲氨基苯基膦)四溴双钯(ⅱ)化合物及其制备方法和用途 |
| CN115448892B (zh) * | 2022-09-19 | 2023-07-07 | 郑州铁路职业技术学院 | 一种苯并噻二唑杂环化合物的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8727989D0 (en) * | 1987-11-30 | 1988-01-06 | Merck Sharp & Dohme | Therapeutic agents |
| EP0330788A1 (en) | 1988-03-01 | 1989-09-06 | Merrell Dow Pharmaceuticals Inc. | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia |
| WO2005113542A2 (en) | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| JP2009504773A (ja) * | 2005-08-19 | 2009-02-05 | エラン ファーマシューティカルズ,インコーポレイテッド | ガンマセクレターゼの架橋n−二環式スルホンアミド阻害剤 |
| TW200813054A (en) | 2006-06-02 | 2008-03-16 | Elan Pharm Inc | Fused, tricyclic sulfonamide inhibitors of gamma secretase |
| CN101128035B (zh) | 2006-08-18 | 2011-08-24 | 中兴通讯股份有限公司 | 时分码分多址系统中信道间的定时方法 |
| MX2009012525A (es) * | 2007-05-25 | 2009-12-09 | Elan Pharm Inc | Pirazol-pirrolidinas como inhibidores de gamma secretasa. |
| US8283358B2 (en) | 2008-09-05 | 2012-10-09 | Elan Pharmaceuticals, Inc. | N-sulfonamido polycyclic pyrazolyl compounds |
-
2009
- 2009-09-04 US US12/554,134 patent/US8283358B2/en not_active Expired - Fee Related
- 2009-09-04 EA EA201170421A patent/EA201170421A1/ru unknown
- 2009-09-04 TW TW098129931A patent/TW201014856A/zh unknown
- 2009-09-04 AR ARP090103413A patent/AR073497A1/es not_active Application Discontinuation
- 2009-09-04 AU AU2009289579A patent/AU2009289579A1/en not_active Abandoned
- 2009-09-04 CN CN2009801426386A patent/CN102203089A/zh active Pending
- 2009-09-04 BR BRPI0918213A patent/BRPI0918213A2/pt not_active IP Right Cessation
- 2009-09-04 WO PCT/US2009/055987 patent/WO2010028213A2/en not_active Ceased
- 2009-09-04 EP EP09792258A patent/EP2346863A2/en not_active Withdrawn
- 2009-09-04 PE PE2011000438A patent/PE20110418A1/es not_active Application Discontinuation
- 2009-09-04 CA CA2736767A patent/CA2736767A1/en not_active Abandoned
- 2009-09-04 MX MX2011002047A patent/MX2011002047A/es unknown
- 2009-09-04 JP JP2011526217A patent/JP2012502051A/ja active Pending
- 2009-09-04 KR KR1020117007863A patent/KR20110055715A/ko not_active Withdrawn
-
2011
- 2011-02-17 IL IL211263A patent/IL211263A0/en unknown
- 2011-02-24 CL CL2011000405A patent/CL2011000405A1/es unknown
- 2011-03-16 ZA ZA2011/01994A patent/ZA201101994B/en unknown
- 2011-03-31 CO CO11039494A patent/CO6362008A2/es not_active Application Discontinuation
- 2011-04-01 MA MA33737A patent/MA32688B1/fr unknown
- 2011-04-01 EC EC2011010947A patent/ECSP11010947A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2346863A2 (en) | 2011-07-27 |
| IL211263A0 (en) | 2011-04-28 |
| US20100081680A1 (en) | 2010-04-01 |
| EA201170421A1 (ru) | 2012-01-30 |
| ECSP11010947A (es) | 2011-07-29 |
| BRPI0918213A2 (pt) | 2015-12-08 |
| CO6362008A2 (es) | 2012-01-20 |
| MX2011002047A (es) | 2011-06-17 |
| AU2009289579A1 (en) | 2010-03-11 |
| AR073497A1 (es) | 2010-11-10 |
| TW201014856A (en) | 2010-04-16 |
| WO2010028213A2 (en) | 2010-03-11 |
| US8283358B2 (en) | 2012-10-09 |
| PE20110418A1 (es) | 2011-06-22 |
| ZA201101994B (en) | 2011-11-30 |
| CN102203089A (zh) | 2011-09-28 |
| CL2011000405A1 (es) | 2011-07-01 |
| MA32688B1 (fr) | 2011-10-02 |
| WO2010028213A3 (en) | 2010-06-03 |
| CA2736767A1 (en) | 2010-03-11 |
| JP2012502051A (ja) | 2012-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8283358B2 (en) | N-sulfonamido polycyclic pyrazolyl compounds | |
| CN101501032B (zh) | 作为γ-分泌酶抑制剂的稠合的三环磺酰胺 | |
| US7754712B2 (en) | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | |
| EP2152713B1 (en) | Pyrazolopyrrolidines as inhibitors of gamma secretase | |
| HK1132270A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| MX2008006806A (en) | 5-(arylsulfonyl)-pyrazolopiperidines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20110405 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |